. "Chaudhury S, Reshef R, Nikiforow S, et al. Subgroup analysis in pediatric patients from the phase 3 study of tabelecleucel for allogeneic or solid organ transplant recipients with Epstein–Barr virus-driven post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE). Blood. 2025;146(suppl 1):5488.." Blood, 2026. doi:10.1182/blood.2026033859